Vanda's Launch Season: NEREUS Inflection and Pipeline Readouts in a Cash-Tight Year
A small-cap biopharma bets on consumer-driven motion sickness and a slate of late-stage catalysts while managing a declining legacy product.
VNDA · Earnings Call · 2026-08-05
NEREUS: The Consumer Bet
Vanda's second-quarter report marks a pivotal shift: the company launched NEREUS (tradipitant) for motion sickness in May 2026, its first direct-to-consumer product. The company booked only $1 million in sales but constrained $12.6 million of revenue due to wholesale inventory build. As Kevin Moran explained, “NEREUS net product sales were $1 million for the first 6 months of 2026.” — Kevin Patrick Moran, Chief Financial Officer · 2026-08-05 That conservative accounting reflects the uncertainty of early patient demand, but it also telegraphs the company's strategy to build a consumer-driven channel. With Personal promotion expected to start later this year, the launch is just beginning. The company's bet on a cash-pay, web-based model is unique in this space. NEREUS launched and constrained revenue are two new keywords this quarter, signaling a fresh narrative.Fanapt and the Pipeline
Fanapt continues to deliver: TRx growth of 31% and NBRx growth of 32% year-over-year, fueled by the bipolar indication expansion. The company is also preparing to launch BYSANTI, a close analog, in the second half of 2026, with a more favorable gross-to-net profile. As Mihael noted, “We are pleased with the continued strong growth of Fanapt and the enthusiastic response to NEREUS as it becomes available to patients.” — Mihael H. Polymeropoulos, Chief Executive Officer · 2026-08-05 Meanwhile, the pipeline has multiple readouts: the Phase 3 for NEREUS in GLP-1-induced vomiting, VQW-765 for social anxiety, HETLIOZ for delayed sleep phase, and BYSANTI for MDD. The company's cash runway extends through 2027, but the burn is high. Operating income deteriorated to -$50M in the latest quarter, a 22% yoy drop.Financial Squeeze and the Hetlioz Drag
The financial picture is strained. HETLIOZ is facing generic competition and shipment timing issues (a $7M order arriving July 1 pushed revenue to Q3). Net loss widened to $62.5M in Q2 2026. The company expects operating expenses to moderate as Phase 3 programs conclude, but the current cash position of $170M must last through 2027. As Mihael stated, “We believe that our current resources together with anticipated project revenues provide a solid foundation to advance our objectives through at least the end of 2 thousand 27.” — Mihael H. Polymeropoulos, Chief Executive Officer · 2026-08-05 Yet the stock has fallen 30% in the last 90 days, reflecting investor skepticism about the commercial scaling. Prior call quotes confirm the build-up: on Nereus modeling, Kevin said “It is informed by modeling and what we have seen in some of our qualitative and quantitative research.” — Kevin Moran, Chief Financial Officer · 2026-05-06 And earlier, Mihael on commercial availability “We expect available commercial materials, either by late Q2 or beginning of Q3.” — Mihael Polymeropoulos, Chief Executive Officer · 2026-02-11Vanda is at an inflection, but the market is cautious. The consumer experiment with NEREUS and the upcoming launches of BYSANTI and Imsidolimab could redefine the company, yet the cash burn and competitive pressures on HETLIOZ temper the optimism. The next few quarters will be decisive.We constrain NEREUS net product sales to an amount probable of significant revenue reversal. The constrained revenue of $12.6 million relates to the uncertainties of patient demand and product returns related to the elevated levels of inventory on hand at wholesalers.